Biological
Recombinant Human Papillomavirus 11-valent Vaccine clinical trials
Keep track of what changes. Save the Recombinant Human Papillomavirus 11-valent Vaccine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Recombinant Human Papillomavirus 11-valent Vaccine is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 YearsRecruitingPhase 3National Vaccine and Serum Institute, ChinaNCT05262010Written as 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
- Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)CompletedPhase 2National Vaccine and Serum Institute, ChinaNCT04436133Written as Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
- A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 YearsCompletedPhase 1National Vaccine and Serum Institute, ChinaNCT04083196Written as 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)